Full-year 2022 Results
Fourth Quarter
Full-year 2022 Results
Delivering on our purpose of using the power of leading-edge science
to save and improve lives around the world
Strong revenue growth
MSD
Strategic business development
Scientific, commercial and operational success
Worldwide Sales
GAAP EPS
Non-GAAP EPS1
Strong Q4 performance reflects
continued business momentum
$13.8B
$1.18
$1.62
Full-year 2022 results reflect
sustained revenue growth
$59.3B
$5.71
$7.48
2023 financial outlook
$57.2B
$5.86
$6.80
to
to
to
$58.7B
$6.01
$6.95
Full-year 2022 Sales
KEYTRUDA
(pembrolizumab) Injection 100 mg
GARDASIL.
[Human Papillomavirus Quadrivalent
(Types 6, 11, 16, and 18) Vaccine, Recombinant]
GARDASIL.9
Human Papillomavirus
9-valent Vaccine, Recombinant
Lagevrio²
molnupiravir
MSD
Animal Health
$20.9B
$6.9B
$5.7B
$5.5B
"2022 was an exceptional year for MSD, which is a testament to the profound impact our medicines and vaccines
are having on patients globally.
I am extremely proud of what our talented and dedicated colleagues have accomplished scientifically,
commercially and operationally. Our science-led strategy is working as we continue to build a sustainable engine
that will drive innovation and generate long-term value for patients and shareholders well into the next decade."
Rob Davis
Chairman and Chief Executive Officer, MSD
1. A reconciliation of GAAP to non-GAAP EPS can be found in the company's earnings release.
2. LAGEVRIO is not approved, but is authorized for emergency use by the FDA.View entire presentation